FDA Grants Rare Hearing for Vanda’s Jet Lag Drug After Court Reversal

Event summary

  • FDA granted Vanda’s request for a formal evidentiary public hearing on March 2, 2026, to review its proposed refusal to approve HETLIOZ® for jet lag disorder.
  • This marks the first such hearing in over 40 years, underscoring the significance of the legal and scientific issues involved.
  • The hearing follows a D.C. Circuit Court ruling in August 2025 that set aside the FDA’s earlier refusal, criticizing the agency’s handling of Vanda’s evidence.
  • HETLIOZ® is currently approved for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome, with the pending sNDA seeking expansion into jet lag disorder.

The big picture

The FDA’s decision to grant a formal evidentiary hearing for Vanda’s HETLIOZ® application is a rare and significant regulatory step, highlighting the tension between scientific evidence and regulatory discretion. This development follows a court ruling that criticized the FDA’s handling of Vanda’s evidence, suggesting a potential shift in the balance of power between pharmaceutical companies and regulators. The outcome of the hearing could set a precedent for future drug approval processes, particularly in cases involving novel applications of existing therapies.

What we're watching

Regulatory Precedent
Whether the FDA’s decision to grant a hearing signals a broader shift toward greater transparency and procedural fairness in drug approvals.
Legal Strategy
How Vanda’s persistence in advocating for its jet lag application may influence future regulatory disputes between pharmaceutical companies and the FDA.
Market Opportunity
The potential impact of HETLIOZ®’s approval for jet lag disorder on Vanda’s revenue, given the lack of current FDA-approved treatments for this condition.